Patient, disease, and transplantation characteristics
| . | ATG, no. (%) . | Alemtuzumab, no. (%) . | T cell–replete, no. (%) . | P . |
|---|---|---|---|---|
| No. of patients | 584 | 213 | 879 | |
| Age, y | .16 | |||
| 21-29 | 39 (7) | 9 (4) | 54 (6) | |
| 30-39 | 59 (10) | 27 (13) | 91 (10) | |
| 40-49 | 92 (16) | 47 (22) | 179 (20) | |
| 50-59 | 235 (40) | 70 (33) | 342 (39) | |
| 60-69 | 159 (27) | 60 (28) | 213 (24) | |
| Disease | < .001 | |||
| Acute myeloid leukemia | 214 (37) | 55 (26) | 272 (31) | |
| Acute lymphoblastic leukemia | 18 (3) | 7 (3) | 39 (4) | |
| Chronic myeloid leukemia | 51 (9) | 9 (4) | 63 (7) | |
| Chronic lymphocytic leukemia | 58 (10) | 32 (15) | 99 (11) | |
| Myelodysplastic syndrome | 66 (11) | 13 (6) | 81 (9) | |
| Non-Hodgkin lymphoma* | 136 (23) | 85 (40) | 274 (31) | |
| Hodgkin lymphoma† | 41 (7) | 12 (6) | 51 (6) | |
| Disease status before transplantation | .28 | |||
| Early | 193 (33) | 58 (27) | 271 (31) | |
| Advanced | 391 (67) | 155 (73) | 608 (69) | |
| Performance score before transplantation | .08 | |||
| < 90%s | 188 (32) | 47 (22) | 264 (30) | |
| 90%-100% | 352 (60) | 135 (63) | 551 (63) | |
| Not reported | 44 (8) | 31 (15) | 64 (7) | |
| Conditioning regimen | < .001 | |||
| Busulfan + fludarabine | 375 (54) | 42 (20) | 300 (34) | |
| Melphalan + fludarabine | 132 (23) | 81 (38) | 310 (35) | |
| Cyclophosphamide+fludarabine | 77 (13) | 90 (42) | 269 (31) | |
| Graft type | .001 | |||
| Bone marrow | 84 (14) | 36 (17) | 83 (9) | |
| Peripheral blood progenitor cells | 500 (86) | 177 (83) | 796 (91) | |
| GVHD prophylaxis | < .001 | |||
| Cyclosporine alone | 68 (12) | 37 (17) | 95 (11) | |
| Cyclosporine + methotrexate | 91 (16) | 31 (15) | 243 (28) | |
| Cyclosporine + other agents | 79 (14) | 19 (9) | 103 (12) | |
| Tacrolimus alone | 30 (5) | 54 (25) | 11 (1) | |
| Tacrolimus + methotrexate | 242 (41) | 57 (27) | 329 (37) | |
| Tacrolimus + other agents | 74 (13) | 15 (7) | 98 (11) | |
| Donor-recipient CMV serostatus | < .001 | |||
| Donor and recipient seronegative | 161 (28) | 54 (25) | 188 (21) | |
| Donor seropositive/recipient seronegative | 71 (12) | 20 (9) | 85 (10) | |
| Donor seronegative/recipient seropositive | 156 (27) | 81 (38) | 198 (23) | |
| Donor and recipient seropositive | 185 (32) | 54 (25) | 361 (41) | |
| Unknown | 11 (2) | 4 (2) | 47 (5) | |
| Donor type | < .001 | |||
| HLA-matched sibling | 228 (39) | 47 (22) | 517 (59) | |
| Unrelated, 8/8 matched | 251 (43) | 121 (57) | 278 (32) | |
| Unrelated, 7/8 matched | 105 (18) | 45 (21) | 84 (10) | |
| Year of transplantation | < .001 | |||
| 2000-2003 | 176 (30) | 66 (31) | 353 (40) | |
| 2004-2007 | 408 (70) | 147 (69) | 526 (60) |
| . | ATG, no. (%) . | Alemtuzumab, no. (%) . | T cell–replete, no. (%) . | P . |
|---|---|---|---|---|
| No. of patients | 584 | 213 | 879 | |
| Age, y | .16 | |||
| 21-29 | 39 (7) | 9 (4) | 54 (6) | |
| 30-39 | 59 (10) | 27 (13) | 91 (10) | |
| 40-49 | 92 (16) | 47 (22) | 179 (20) | |
| 50-59 | 235 (40) | 70 (33) | 342 (39) | |
| 60-69 | 159 (27) | 60 (28) | 213 (24) | |
| Disease | < .001 | |||
| Acute myeloid leukemia | 214 (37) | 55 (26) | 272 (31) | |
| Acute lymphoblastic leukemia | 18 (3) | 7 (3) | 39 (4) | |
| Chronic myeloid leukemia | 51 (9) | 9 (4) | 63 (7) | |
| Chronic lymphocytic leukemia | 58 (10) | 32 (15) | 99 (11) | |
| Myelodysplastic syndrome | 66 (11) | 13 (6) | 81 (9) | |
| Non-Hodgkin lymphoma* | 136 (23) | 85 (40) | 274 (31) | |
| Hodgkin lymphoma† | 41 (7) | 12 (6) | 51 (6) | |
| Disease status before transplantation | .28 | |||
| Early | 193 (33) | 58 (27) | 271 (31) | |
| Advanced | 391 (67) | 155 (73) | 608 (69) | |
| Performance score before transplantation | .08 | |||
| < 90%s | 188 (32) | 47 (22) | 264 (30) | |
| 90%-100% | 352 (60) | 135 (63) | 551 (63) | |
| Not reported | 44 (8) | 31 (15) | 64 (7) | |
| Conditioning regimen | < .001 | |||
| Busulfan + fludarabine | 375 (54) | 42 (20) | 300 (34) | |
| Melphalan + fludarabine | 132 (23) | 81 (38) | 310 (35) | |
| Cyclophosphamide+fludarabine | 77 (13) | 90 (42) | 269 (31) | |
| Graft type | .001 | |||
| Bone marrow | 84 (14) | 36 (17) | 83 (9) | |
| Peripheral blood progenitor cells | 500 (86) | 177 (83) | 796 (91) | |
| GVHD prophylaxis | < .001 | |||
| Cyclosporine alone | 68 (12) | 37 (17) | 95 (11) | |
| Cyclosporine + methotrexate | 91 (16) | 31 (15) | 243 (28) | |
| Cyclosporine + other agents | 79 (14) | 19 (9) | 103 (12) | |
| Tacrolimus alone | 30 (5) | 54 (25) | 11 (1) | |
| Tacrolimus + methotrexate | 242 (41) | 57 (27) | 329 (37) | |
| Tacrolimus + other agents | 74 (13) | 15 (7) | 98 (11) | |
| Donor-recipient CMV serostatus | < .001 | |||
| Donor and recipient seronegative | 161 (28) | 54 (25) | 188 (21) | |
| Donor seropositive/recipient seronegative | 71 (12) | 20 (9) | 85 (10) | |
| Donor seronegative/recipient seropositive | 156 (27) | 81 (38) | 198 (23) | |
| Donor and recipient seropositive | 185 (32) | 54 (25) | 361 (41) | |
| Unknown | 11 (2) | 4 (2) | 47 (5) | |
| Donor type | < .001 | |||
| HLA-matched sibling | 228 (39) | 47 (22) | 517 (59) | |
| Unrelated, 8/8 matched | 251 (43) | 121 (57) | 278 (32) | |
| Unrelated, 7/8 matched | 105 (18) | 45 (21) | 84 (10) | |
| Year of transplantation | < .001 | |||
| 2000-2003 | 176 (30) | 66 (31) | 353 (40) | |
| 2004-2007 | 408 (70) | 147 (69) | 526 (60) |
N = 405 received rabbit ATG; n = 148 received < 6 mg/kg total dose; n = 110 received 6-8 mg/kg, and n = 147 received > 8 mg/kg. N = 160 received horse ATG; n = 27 received < 30 mg/kg total dose; n = 93 received 30-50 mg/kg, and n = 40 received > 50 mg/kg.
CMV indicates cytomegalovirus.
N = 142 (29%) patients had prior autologous transplantation.
N = 92 (88%) patients had prior autologous transplantation.